Mansfield C, Botha W, Vondeling GT, Klein K, Wang K, Singh J, Hackshaw MD. Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study. Breast Cancer. 2023 Jan;30(1):23-35. doi: 10.1007/s12282-022-01394-6
Henk HJ, Kaye JA, Rothman KJ, Becker LK, Legg JC, Li X. Variation by age in neutropenic complications among patients with cancer receiving chemotherapy. Community Oncol. 2013 Jan 1;10(1):16-26.
Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Community Oncol. 2009 Nov 1;6(11):494-502.
Buchanan A, Sugg Skinner C, Calingaert B, Schildkraut J, King R, Marcom K. Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. Community Oncol. 2009;6(2):70-7.
Albino AP, Huang X, Jorgensen ED, Yang J, Gietl D, Traganos F, Darzynkiewicz Z. Induction of H2AX phosphorylation in pulmonary cells by tobacco smoke: a new assay for carcinogens. Cell cycle. 2004 Aug 3;3(8):1062-8. doi: 10.4161/cc.3.8.988
Kovac AL, Pearman MH, Khalil SN, Scuderi PE, Joslyn AF, Prillaman BA, Cox F. Ondansetron prevents postoperative emesis in male outpatients.S3A-379 study group. J Clin Anesth. 1996 Dec;8(8):644-51. doi: 10.1016/s0952-8180(96)00173-0